Sanofi and Amgen Inc. are turning to heavyweight appellate talent as they prepare to duke it out over an injunction that orders Sanofi’s Praluent cholesterol medicine off the market.
Kirkland & Ellis partner Paul Clement filed Sanofi’s motion for an emergency stay Jan. 13 evening at the U.S. Court of Appeals for the Federal Circuit. Failing to grant it, he wrote, would deprive thousands of patients “life-saving” medicine, throw Sanofi employees out of work and renegotiate contracts with insurers and pharmacy benefit managers. “The district court recognized that this extraordinary remedy was contrary to the public interest, but ordered it anyway,” he wrote.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
